In the present report we demonstrate that the IL-6 gene is expressed in anti-Ig-activated and neoplastic B cells. After activation with anti-Ig, splenic B cells rapidly expressed mRNA with peak expression occurring at 4 h and declining rapidly thereafter. In an attempt to exclude that the IL-6 mRNA expression was in non-B cells, T cells and monocytes were extensively depleted. In this highly purified B cell population, IL-6 mRNA was retained, whereas the expression of the T cell-and monocyte-restricted CD2 and CD14 genes was nearly undetectable. These results are consistent with the conclusion that activated B cells express IL-6 mRNA. Because we found IL-6 mRNA expression in normal activated B lymphocytes, we examined the expression of IL-6 mRNA in B cell neoplasms. 11 of 25 non-Hodgkins B cell lymphomas and 4 of 4 myelomas and plasma cell leukemias expressed IL-6 mRNA, whereas only 1 of 19 B cell leukemias was positive. To exclude that IL-6 mRNA expression in neoplastic B cells was the result of contaminating non-B cells, T cells and monocytes were extensively depleted from the tumor specimens. In the three IL-6-positive tumor samples depleted of T cells and monocytes, IL-6 mRNA expression was retained in all cases. These observations provide support for the idea that the IL-6 gene is expressed in normal activated and neoplastic B cells.
Introduction
A number of soluble factors have been shown to regulate the growth and differentiation of murine and human B lymphocytes. Recently, several of these factors have been molecularly and functionally characterized and their genes have been cloned (1) (2) (3) (4) (5) . Functional studies using recombinant factors demonstrate that individual cytokines can activate resting B cells (6) , induce proliferation of activated B cells (5, 7) , regulate isotype expression (8) , or induce Ig secretion (9) .
One of these cytokines, termed IL-6, was shown to be one of the major factors necessary for the terminal differentiation of activated B cells into Ig-secreting cells (9) . IL-6 was first identified in the culture supernatant of PHA-stimulated PBL (10) . Although initially isolated from a transformed T cell line Receivedfor publication 7 September 1988 and in revisedform 30 November 1988. creted by other cell types (12) (13) (14) . Within the hematopoietic system, monocytes appear to be the major producer (14) .
Moreover, recent studies demonstrate that fibroblasts, endothelial cells, and some epithelial tumors have the capacity to secrete IL-6. In addition to its ability to induce activated B cells to secrete Ig, human IL-6 has been shown to induce the growth of murine plasmacytomas (15) , hybridomas (14) , and EBVinfected human B lymphocytes (16) . Although initially thought to be a B cell-restricted cytokine, it has become increasingly clear that IL-6 has a multitude of additional effects on hematopoietic and nonhematopoietic cells. To date, these include antiviral activity (12) (cloned as IFN p2), granulocyte/ macrophage CSA (17) , cytotoxic T cell differentiation activity (18) , and induction of acute phase protein expression by the liver ( 19) . IL-6 also has several IL-l-like activities that include costimulation of thymocyte proliferation (20) , activation of T lymphocytes (21) , and induction of fever.
In addition to its production by normal cells, preliminary evidence suggested that IL-6 could also be produced by neoplastic cells. Hirano et al. initially demonstrated that some cardiac myxomas produce IL-6, and suggested that many of the autoimmune characteristics of this disease might be secondary to IL-6 secretion (4). Recently, Kawano and his colleagues have demonstrated that IL-6 is produced by human myelomas (22) . These tumors appear to proliferate in response to IL-6; moreover, this proliferation is specifically inhibited by antibodies directed against IL-6. The production of IL-6 by myelomas suggests that IL-6 is involved in the growth of these terminally differentiated neoplastic B cells.
Malignant transformation leading to unrestricted cell growth may occur when a cell acquires the ability to produce and respond to endogenous factors via cell surface or intracytoplasmic receptors. This process has been termed autocrine stimulation (23) . The evidence that IL-6 is important in the differentiation ofactivated B lymphocytes and in the growth of myelomas suggests that IL-6 might function as a growth factor for neoplastic B cells. To address this question, we have examined whether the IL-6 gene is expressed in a variety of B cell tumors and after activation of resting B lymphocytes in vitro. In the studies to be reported below, we demonstrate that antiIg-activated B cells and B cell neoplasms that correspond to mid-to later stages of differentiation appear to express this gene. (30) . The identity of the clone was confirmed by restriction enzyme digest, partial sequencing, and bioassay. After transfection of IL-6 cDNA-pcD DNA into cos cells, the supernatant was harvested at 72 h and assayed for stimulation of Ig production by anti-Ig activated B cells.
Methods
When the full-length IL-6 cDNA insert was used as a probe in Northern blot analyses of total cellular RNA, cross-hybridization was seen to I8s rRNA as well as to the authentic 1,300-nucleotide IL-6 mRNA. This result was also seen using a full-length (15 ug) of total cellular RNA prepared at distinct times points after activation. Fig. 1 demonstrates that equal amounts of RNA were studied, as evidenced by the equal staining intensity of the ribosomal RNAs with ethidium bromide.
The level of IL-6 mRNA was extremely low in unstimulated B cells (Fig. 1 ). After activation with anti-Ig, IL-6 mRNA was rapidly induced with 1.3-and 2.3-fold increases observed at 10 and 30 min, respectively. Initially, two closely spaced bands (1.3 and 1.4 kb) could be discerned. By 4 h, expression was maximal (21.4-fold increase), with only an intense 1.3-kb band observed. Expression declined rapidly after 8 h, with minimal mRNA being detected at 24 h (0.7-fold) and none detected thereafter. When protein synthesis was blocked with cycloheximide, an additional 3.2-fold increase in IL-6 mRNA expression at 8 h was seen. Similar data was observed for cells from three different spleens and a representative experiment is shown in Fig. 1 levels by immunomagnetic depletion. The blot was also rehybridized with the T cell-specific probe, CD2 (T 11). (Fig. 1) . The level ofc-myc expression was extremely low in the unstimulated splenic E-population. After activation, c-myc mRNA levels increased threefold within the period between 10 and 30 min. At 4 h after activation the level of c-myc expression had increased 153-fold, as compared with the unstimulated population. After 4 h the level of c-myc mRNA declined rapidly, reaching low levels by 48 h. Cycloheximide treatment led to an additional 12-fold increase in the levels of c-myc mRNA at 8 h. Like c-myc mRNA, the level of IL-2R mRNA was extremely low in unstimulated splenic E-cells and demonstrated no increase within the first 30 min after activation with anti-Ig. However, by 4 h the level had increased 40-fold. The maximal expression was seen at 8 h with both the 1.5-and 3.5-kb mRNAs expressed and peaking with a 78-fold increase. The IL-2R 3.5-kb mRNA was 3-4-fold more intense than the 1.5-kb mRNA band. In activated T cells the 1.5-kb mRNA is usually more intense (31) . In contrast to IL-6 and c-myc, the decrease in IL-2R mRNA was gradual and was still -25% of maximal levels at 72 h. Cycloheximide treatment led to an additional 2.4-fold increase in the level of IL-2-R mRNA at 8 h.
IL (Fig. 4, top) . Each of the purified tumor samples retained IL-6 gene expression and the level was 
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Daudi, and Namalwa, and the IL-6-responsive, lymphoblastoid line, CESS. Of five myeloma cell lines tested, only U266 was positive, whereas the HS-Sultan, IM-9, RPMI 8226, and ARH 77 myeloma lines were negative. The K562 erythroleukemia and the Rex T cell leukemia lines were also negative.
Discussion
In the present report we demonstrate that the IL-6 gene is expressed in anti-Ig activated and neoplastic B cells. After activation with anti-Ig, splenic E-cells rapidly expressed IL-6 mRNA with peak expression occurring at 4 h and declining rapidly thereafter. In an attempt to exclude that the IL-6 mRNA expression was in non-B cells, we extensively depleted T cells and monocytes. In this highly purified population, IL-6 mRNA was retained, whereas the expression of the T cell-and monocyte-restricted CD2 and CD14 genes were nearly undetectable. These results are consistent with the Possibly in tumor cell lines a stage of autocrine dependence may be superceded by further oncogenic changes. In addition to autocrine effects, IL-6 expression by a tumor may be responsible for systemic effects including fever, induction of acute phase proteins in the liver, and stimulation of hematopoiesis. Furthermore, secreted IL-6 might stimulate the proliferation of latently EBV-infected B cells.
In summary, we have observed that normal activated B cells and some neoplastic B cells express IL-6 mRNA. The specific biologic role of B cell-derived IL-6 is not currently known; however, this growth and differentiation factor appears to have a very wide array of functions. Its expression at an early stage of B cell activation and in more differentiated B cell tumors suggests a biologically important role for B cell-derived IL-6. We plan to examine the secretion of IL-6 by normal and neoplastic B cells and its effects on cells of the microenvironment.
